Will DCH's net leverage remain above 3.0x through Q3 2026?

Starting at ~3.1x with $4.2B net debt and $1,350M EBITDA midpoint. To get below 3.0x, DCH needs either: (a) reduce net debt by ~$150M, or (b) increase EBITDA to ~$1,400M, or some combination. The analysis shows only ~$50M true free cash for debt paydown at the high end of guidance after integration costs. Through Q3 (9 months), perhaps $35-40M of debt reduction. EBITDA would need to be tracking above $1,400M annualized to offset. With only $50-75M synergy P&L flow-through, the math is tight. Leverage likely stays above 3.0x through Q3.

The math strongly favors remaining above 3.0x. However, there are scenarios where leverage could drop faster: (1) asset sales — if DCH divests non-core operations, proceeds could accelerate debt reduction, (2) working capital release — integration often frees working capital as inventory and receivables are rationalized, (3) better-than-expected EBITDA if synergies flow faster than guided. Management has said deleveraging is the 'top priority,' which could include asset sales not in current guidance. But the base case is still above 3.0x through Q3.

The question asks about remaining above 3.0x through Q3 — that's only 7-8 months from the close date. In that period, integration cash costs ($210-275M annualized) are consuming nearly all free cash flow. The reported leverage figure uses LTM EBITDA, which means Q3 LTM would still include some pre-acquisition quarters with only standalone AAM EBITDA. This could actually make the leverage ratio look worse, not better, depending on how management reports pro forma figures. I assign high probability to remaining above 3.0x.

This is straightforward math. Starting at 3.1x. To get to 3.0x in 7-8 months requires either ~$140M debt reduction or meaningful EBITDA growth. With true free cash of ~$50M at the HIGH end and front-loaded integration costs, debt paydown of $140M is unrealistic without asset sales. EBITDA growth from synergies of $50-75M P&L for the full year means only ~$35-55M would flow through by Q3. Not enough to move the ratio 0.1x. The most likely outcome is leverage stays in the 3.0-3.1x range through Q3, and 3.0x itself would require optimistic assumptions.

While the base case strongly favors above 3.0x, I note that management stated deleveraging is the 'top priority.' This could include: non-core asset divestitures from the combined portfolio, strategic disposition of underperforming plants, or cash from GKN operations that was not in the standalone AAM model. The combined entity has more levers than standalone AAM did. But even accounting for these, 3.0x by Q3 would require everything going right. More realistic to expect 3.0-3.1x at Q3, crossing below 3.0x in Q4 or early 2027.

The mechanics of leverage reduction in the first year of integration strongly favor YES. Integration costs are front-loaded (Q1-Q2 heaviest), consuming free cash flow. Synergy benefits ramp over the year but don't generate enough EBITDA improvement by Q3 to move the needle. Even in the most optimistic scenario (high end of FCF guidance, $325M, with only $210M integration costs = $115M for debt paydown), $115M of debt reduction on $4,200M base = 2.7% reduction. Leverage drops from 3.1x to maybe 3.05x. Still above 3.0x.

Starting at 3.1x with minimal free cash for debt paydown (~$50M at high end). Synergy P&L of $50-75M full year means limited EBITDA uplift by Q3. Math strongly favors staying above 3.0x through Q3.

The math is clear: ~$50M free cash for debt reduction is a fraction of the $140M+ needed to cross 3.0x. Asset sales could change this but are speculative. High probability of remaining above 3.0x.

Front-loaded integration costs plus limited synergy P&L by Q3 make sub-3.0x leverage very difficult in this timeframe. Management's own guidance implies leverage stays elevated through 2026. High confidence in YES.